3 results
Approved WMOCompleted
To investigate the effect of various dose regimens of Cyclogest® on secretory transformation of the endometrium in comparison to Crinone® and placeboTo investigate single and multiple dose pharmacokinetics of Cyclogest®To investigate safety and…
Approved WMOCompleted
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic renal cell carcinoma (RCC) with a clear-cell component, who progressed…
Approved WMOCompleted
The objective of this study is to evaluate the efficacy of oral cabozantinib at adaily dose of 60 mg compared with 140 mg in subjects with progressive,metastatic MTC.